Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة الأردنية لإنتاج الأدوية - jordan pharmaceutical manufacturer (jpm) - fluoxetine 20 mg - 20 mg

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة الأردنية لإنتاج الأدوية - jordan pharmaceutical manufacturer (jpm) - fluoxetine 20 mg - 20 mg

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة الأردنية لإنتاج الأدوية - jordan pharmaceutical manufacturer (jpm) - fluoxetine 20 mg - 20 mg

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة الأردنية لإنتاج الأدوية - jordan pharmaceutical manufacturer (jpm) - fluoxetine 20 mg - 20 mg

Israel - English - Ministry of Health

unipharm ltd, israel - bisoprolol fumarate - tablets - bisoprolol fumarate 5 mg - bisoprolol - bisoprolol - management of angina pectoris, hypertention. treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function ( ejection fraction < 35 %, determined by echocardiography) in addition to ace inhibitors and diuretics, and optionally cardiac glycosides.

Israel - English - Ministry of Health

unipharm ltd, israel - bisoprolol hemifumarate - tablets - bisoprolol hemifumarate 2.5 mg - bisoprolol - bisoprolol - treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function ( ejection fraction < 35 %, determined by echocardiography) in addition to ace inhibitors and diuretics, and optionally cardiac glycosides.

Israel - English - Ministry of Health

unipharm ltd, israel - bisoprolol hemifumarate - film coated tablets - bisoprolol hemifumarate 1.25 mg - bisoprolol - bisoprolol - treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function (ejection fraction < 35%, determined by echocardiography) in addition to ace inhibitors and diuretics, and optionally cardiac glycosides

Israel - English - Ministry of Health

unipharm ltd, israel - pravastatin sodium - tablets - pravastatin sodium 40 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet other nonpharmacological measures alone have been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death due to non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previ

Israel - English - Ministry of Health

unipharm ltd, israel - pravastatin sodium - tablets - pravastatin sodium 10 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet and other nonpharmacological measures alone has been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - levothyroxine sodium - tablets - levothyroxine sodium 100 mcg - levothyroxine sodium - levothyroxine sodium - treatment of hypothyroidism, cretinism and juvenile myxoedema.